Thank you, Madam Chair.
I have a few questions to ask and hope you can answer within the time.
Ms. Fletcher made a comment a little while back about the vaccine potentially affecting autoimmune diseases. I thought maybe we'd get Mr. Griffiths' response to that, because we didn't have time allotted in that questioning for it. Second, could you expand upon the encouraging signs we've heard about from Australia with the H1N1 there?
I want to touch a little bit more upon domestic production. I've heard the comments about how there needs to be a second supplier. Would that production be 100% domestic as well? Could you also expand upon why the GSK has viewed that as important and could they handle all the production with a border shutdown?